Skip to content

Net Income at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$19.63M-49.3%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$49.66M-2.4%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$78.69M-46.3%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$44.9M+11.7%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$69.23M-5.6%
Alumis Inc. logo
Alumis Inc.ALMS
-$93.05M+6.0%

Other financials

Income statement

See full
Revenue$900.0K+12.5%
Operating income-$47.9M-80.1%
EPS (diluted)-$0.11+57.7%

Balance sheet

See full
Cash & equivalents$229.2M+1,668%
Total debt$6.1M-15.7%
Total equity$207.9M+7,069%
Total assets$266.4M+427%

Cash flow

See full
Operating cash flow-$49.1M-149%
CapEx$400.0K
Free cash flow-$49.5M-151%

Valuation

See full
Market cap$923.31M+259%
Enterprise value$700.21M+179%
P/S159.6×+87.1×

Profitability

See full
Operating margin-2,910.4%-265pp
Net margin-2,895.4%-257pp
FCF margin-2,619.5%+69.9pp

Returns & leverage

See full
Return on equity-158.9%-26.4pp
Debt / equity-2.5×
Current ratio4.8×+4.0×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DBV Technologies's net income?
DBV Technologies (DBVT) reported net income of -$47.6M in Q1 2026.
How has DBV Technologies's net income changed year-over-year?
DBV Technologies's net income decreased by 75.6% year-over-year, from -$27.1M to -$47.6M.
What is the long-term trend for DBV Technologies's net income?
Over 4 years (2021 to 2025), DBV Technologies's net income has grown at a 10.7% compound annual growth rate (CAGR), from -$97.81M to -$146.97M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.